Internewscast
Image default
Home » First UK patient given experimental arthritis drug in trial for severe coronavirus
Health News UK

First UK patient given experimental arthritis drug in trial for severe coronavirus

Dr Andy Martin, Intensive Care and Anaesthesia Consultant and study lead (Principal Investigator) of the OSCAR study at Manchester Royal Infirmary, where a Manchester man is the first UK patient to have been given an experimental arthritis drug as part of a clinical trial to treat severe Covid-19 and (Left to right) Rose Jama, Senior Clinical Research Nurse, Farhan Hamid, Dr Anthony Wilson, study co-investigator, who recruited Mr Hamid to a trial where he is the first UK patient to have been given an experimental arthritis drug as part of a clinical trial to treat severe Covid-19.
Manchester Royal Infirmary is the first UK hospital to take part in the Oscar study (Picture: PA

A man from Manchester has become the first UK patient to be given a new experimental treatment for the treatment of severe coronavirus.

In addition to regular treatment in an intensive care unit, Farhan Hamid, 41, has been given a dose of otilimab – a drug being tested as a potential for rheumatoid arthritis.

The Manchester Royal Infirmary patient was recruited on September 11, 2020 to take part in a trial to see if the medicine could also treat severe lung disease associated with Covid-19.

It is part of the Oscar (Otilimab in Severe Covid-19 Related Disease) study, funded by UK pharmaceutical giant by GlaxoSmithKline (GSK), who have also been contracted by the Government to develop a potential coronavirus vaccine.

Advertisement

Advertisement

Advertisement

Leading the Manchester Royal Infirmary trial, intensive care and anaesthesia consultant Andy Martin said: ‘The patients eligible to take part in this study are those experiencing very severe lung difficulties due to Covid-19 infection and are receiving oxygen or ventilator support.

‘We are conducting this study to see whether otilimab – which is under investigation as a potential treatment for rheumatoid arthritis – could also potentially ease the effect of coronavirus on the lungs, dampening the impact of the virus on the immune system.’

Oscar is one of a number of Covid-19 studies that have been given urgent public health research status by the Department of Health and Social Care, with trials already underway in the US.

(Left to right) Rose Jama, Senior Clinical Research Nurse, Farhan Hamid, Dr Anthony Wilson, study co-investigator, who recruited Mr Hamid to a trial where he is the first UK patient to have been given an experimental arthritis drug as part of a clinical trial to treat severe Covid-19.
Farhan Hamid has been given Otilimab in addition to regular treatment (Picture: PA)
Dr Andy Martin, Intensive Care and Anaesthesia Consultant and study lead (Principal Investigator) of the OSCAR study at Manchester Royal Infirmary, where a Manchester man is the first UK patient to have been given an experimental arthritis drug as part of a clinical trial to treat severe Covid-19.
Intensive Care and Anaesthesia Consultant and study lead of the OSCAR study at Manchester Royal Infirmary Dr Andy Martin (Picture: PA)

There are plans to recruit 800 patients globally for the study, and GSK has said it is aiming to conduct research at five hospitals in the UK.

Those taking part will be allocated into two groups at random, with half receiving a one-hour, single infusion of otilimab.

Meanwhile others will get a placebo intravenous therapy in addition to standard care.

University of Manchester senior lecturer and clinical lead for all Covid-19-related studies at Manchester University NHS Foundation Trust Dr Tim Felton said: ‘The primary end point of this study is that participants are alive and free of lung failure after 28 days – so this research is potentially life-saving.’

Senior vice president development at GSK Christopher Corsico said: ‘We are continuing to work hard to find solutions to address the pandemic, including exploring potential treatment options for Covid-19 patients.

‘We know that some Covid-19 patients experience an overreaction of their immune system – sometimes referred to as cytokine storm – which can lead to hospitalisation or death.

‘We believe that otilimab might be able to help counter or calm this process.’

The results from the study are expected in the first half of 2021.

Get in touch with our news team by emailing us at [email protected].

For more stories like this, check our news page.

Advertisement

Advertisement

Source:

Related posts

Delayed immune responses may make COVID-19 deadly for elderly people

InterNewsCast

Kate Garraway returns to radio so her husband can listen to her voice from intensive care 

InterNewsCast

Chicago Weather: City officials discuss summer heat safety plan

InterNewsCast

Leave a Comment